Medical weight loss should improve health, not merely produce the fastest possible change on a scale. When treatment substantially reduces appetite and body weight, protecting nutrition, physical capacity and lean tissue becomes part of the clinical plan.
The short answer: effective weight loss usually includes loss of both fat mass and some lean mass. The aim is not to promise zero lean-mass change. It is to make fat loss the dominant change while supporting adequate nutrition, progressive resistance exercise and clinically appropriate monitoring.
Why scale weight is incomplete
Two people can lose the same number of kilograms and have very different outcomes. One may improve waist circumference, blood pressure, glucose control and mobility while maintaining strength. Another may eat too little, become weaker and struggle to meet protein and micronutrient needs. Scale weight alone cannot distinguish between those journeys.
This is why good follow-up asks more than “How much did you lose?” It also asks how the patient is eating, moving, sleeping and functioning; whether side effects are limiting intake; and whether the pace of change remains appropriate.
Lean mass is not the same as muscle
“Lean mass” is often used as if it means skeletal muscle, but the terms are not interchangeable. Body-composition methods generally classify fat mass and fat-free or lean mass. That lean compartment also includes body water, organs, bone and other tissues. A change reported as lean-mass loss therefore should not automatically be described as the same amount of muscle loss.
Measurement method matters too. DXA, bioelectrical impedance and other tools estimate different compartments in different ways. Hydration, glycogen, recent food, exercise and testing conditions can influence results. Trends are most useful when measured consistently and interpreted alongside strength and function.
What the treatment evidence shows
In the DXA substudy of the SURMOUNT-1 trial, 160 participants had body-composition measurements at baseline and 72 weeks. With tirzepatide, average fat-mass reduction was substantially greater than average lean-mass reduction; approximately three quarters of the weight lost was fat mass and one quarter was lean mass. This was a substudy average—not a prediction for every patient—and lean mass should not be equated directly with skeletal muscle.
The 2026 American Diabetes Association obesity standards place the result in a wider context. They note that lean mass commonly falls during meaningful weight reduction, while physical function can still improve. They recommend attention to nutrition, adequate protein and muscle-strengthening activity, with assessment tailored to the patient.
The responsible message is neither “the medicine destroys muscle” nor “muscle does not matter”. Substantial weight loss changes body composition. Clinicians should anticipate that change and manage the modifiable factors around it.
Who may need closer attention?
Monitoring becomes especially important when a patient is older, has low baseline strength or mobility, has experienced previous frailty, is losing weight very rapidly, has persistent nausea or vomiting, follows a highly restrictive diet, or lives with a condition that affects nutrition or exercise capacity. Medicines, kidney function, injuries and the risk of falls can also change the plan.
These factors do not automatically exclude medical weight-loss treatment. They mean the treatment should be more individualised and may require input from a dietitian, physiotherapist, biokineticist or another relevant professional.
Protein: necessary, but not a universal number
Protein supports tissue maintenance and recovery, but there is no single target that suits every patient. Needs depend on body size, age, activity, total energy intake, dietary pattern, treatment response and medical conditions. Kidney disease and other clinical factors may materially change what is appropriate.
In practice, the first step is often to check whether reduced appetite has made ordinary meals too small or too infrequent to cover basic nutrition. A supplement can be useful in selected circumstances, but it should solve a defined problem rather than replace a balanced plan by default.
Resistance exercise belongs in the conversation
Aerobic activity remains valuable for cardiovascular health and fitness. Muscle-strengthening exercise adds a different signal: it asks the body to maintain and adapt muscle tissue. The programme should be progressive, realistic and matched to the patient's starting ability, injuries and medical status.
For someone who is sedentary or clinically vulnerable, “strength training” may begin with supervised basic movement rather than a demanding gym programme. Consistency and safe progression matter more than an impressive first session.
What useful monitoring can include
Not every patient needs every measurement. Depending on the clinical question, follow-up may include:
- weight trajectory and waist circumference;
- dietary intake, protein adequacy, hydration and treatment tolerance;
- strength, mobility and day-to-day function;
- body-composition trends where the result will change care;
- blood pressure, glucose markers and other metabolic outcomes;
- laboratory assessment when symptoms, medicines or nutritional risk make it relevant.
A measurement earns its place when it can change the treatment plan. More data is not automatically better care.
An assessment-first plan
- Establish baseline health, eating pattern, activity, strength and risk factors.
- Set outcomes beyond kilograms, including metabolic health and function.
- Choose evidence-based treatment with realistic expectations.
- Plan nutrition and resistance exercise from the start, not after weakness appears.
- Review tolerance, rate of loss, intake, strength and clinically relevant measurements.
- Adjust the dose, pace, nutrition, activity or wider plan when the evidence from that patient requires it.
Explore Dr Luhard's medical weight-loss approach
Frequently asked questions
Do GLP-1 medicines cause muscle loss?
Weight loss from any effective intervention can include some lean mass as well as fat mass. Lean mass is not identical to skeletal muscle, and study averages do not predict one person's result. Nutrition, resistance exercise, health status and monitoring all matter.
How much protein do I need?
There is no single safe target for everyone. It should be individualised for body size, age, activity, intake, treatment response and conditions such as kidney disease.
Is a body-composition scan essential?
No. It can add useful trend information when interpreted consistently, but hydration and measurement method affect estimates. Strength, function, waist, nutrition and clinical progress may also be important.
Where can I consult Dr Luhard?
Dr Luhard consults through Medify at 265 Main Street, Waterkloof, Pretoria. Send a WhatsApp message to 065 559 5412 to request the most appropriate consultation type.
Make the outcome broader than the scale.
Request a doctor-led medical weight-loss consultation with Dr Luhard in Waterkloof, Pretoria.
Sources and further reading
- American Diabetes Association: Pharmacologic Treatment of Obesity in Adults—2026 Standards of Care
- Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1
- World Health Organization: global guideline on GLP-1 medicines for obesity
Medical disclaimer: This article provides general medical information and does not replace an individual consultation, diagnosis, dietary prescription or exercise clearance. Treatment suitability and monitoring must be determined for the individual patient.